2019
Serum gamma-glutamyltransferase and the overall survival of metastatic pancreatic cancer
Xiao Y, Yang H, Lu J, Li D, Xu C, Risch HA. Serum gamma-glutamyltransferase and the overall survival of metastatic pancreatic cancer. BMC Cancer 2019, 19: 1020. PMID: 31664937, PMCID: PMC6819453, DOI: 10.1186/s12885-019-6250-8.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaMetastatic pancreatic ductal adenocarcinomaOverall survivalSerum GGTSignificant dose-response associationCox proportional hazards modelMetastatic PDAC patientsDose-response associationMetastatic pancreatic cancerPancreatic cancer survivalSpecialized cancer hospitalBlood glucose levelsProportional hazards modelHazard ratioPrognostic roleCancer HospitalPDAC patientsCancer survivalSubgroup analysisPancreatic cancerDuctal adenocarcinomaMetastatic PCCancer occurrenceGlucose levelsMortality risk
2015
Survival in women with ovarian cancer with and without microsatellite instability.
Segev Y, Zhang S, Akbari MR, Sun P, Sellers TA, McLaughlin J, Risch HA, Rosen B, Shaw P, Schildkraut J, Narod SA, Pal T. Survival in women with ovarian cancer with and without microsatellite instability. European Journal Of Gynaecological Oncology 2015, 36: 681-4. PMID: 26775351.Peer-Reviewed Original ResearchConceptsPresence of MSIEpithelial ovarian cancerOvarian cancerMicrosatellite instabilityPrognostic factorsMSI statusNational Cancer Institute criteriaSpecific prognostic factorsPopulation-based studyOvarian cancer patientsHazard ratioPathologic featuresCancer patientsSubgroup analysisDefective mismatch repairSurvival differencesMulti-variate analysisCancerTumor samplesMSI markersSignificant differencesPatientsSurvivalWomenMismatch repair
2009
IGF2R polymorphisms and risk of esophageal and gastric adenocarcinomas
Hoyo C, Schildkraut JM, Murphy SK, Chow W, Vaughan TL, Risch H, Marks JR, Jirtle RL, Calingeart B, Mayne S, Fraumeni J, Gammon MD. IGF2R polymorphisms and risk of esophageal and gastric adenocarcinomas. International Journal Of Cancer 2009, 125: 2673-2678. PMID: 19626700, PMCID: PMC3008656, DOI: 10.1002/ijc.24623.Peer-Reviewed Original ResearchConceptsNonsteroidal anti-inflammatory drugsRisk of esophagealInsulin-like growth factor 2Gastric adenocarcinomaGastric cancerEsophageal squamous cell carcinomaNoncardia gastric adenocarcinomaNoncardia gastric cancerSquamous cell carcinomaExploratory subgroup analysisAnti-inflammatory drugsMannose-6-phosphate/insulin-like growth factor 2 receptorNoncardia adenocarcinomaGrowth factor 2Cigarette smokersCell carcinomaSubgroup analysisGrowth factor 2 receptorInsulin-like growth factor 2 receptorCardia adenocarcinomaFactor 2 receptorG alleleNonsynonymous genetic variantsAdenocarcinomaStudy participants